Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer
BACKGROUND: To compare the efficacy and toxicity of peptide-doxorubicin (PDOX) and doxorubicin (DOX) on nude mice models of human gastric cancer. RESULTS: Both PDOX and DOX could significantly inhibit tumor growth compared with Control (P < 0.05) in both subcutaneous and orthotopic models. Animal...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788612/ https://www.ncbi.nlm.nih.gov/pubmed/29416744 http://dx.doi.org/10.18632/oncotarget.23319 |
_version_ | 1783296106520641536 |
---|---|
author | Zhang, Jue Yuan, Jing-Ping Wang, Qun Shao, Li-Hua Liu, Shao-Ping Firestone, Raymond A. Hong, Ya-Ping Li, Ji-Guo Xin, Yan-Chao Li, Yan |
author_facet | Zhang, Jue Yuan, Jing-Ping Wang, Qun Shao, Li-Hua Liu, Shao-Ping Firestone, Raymond A. Hong, Ya-Ping Li, Ji-Guo Xin, Yan-Chao Li, Yan |
author_sort | Zhang, Jue |
collection | PubMed |
description | BACKGROUND: To compare the efficacy and toxicity of peptide-doxorubicin (PDOX) and doxorubicin (DOX) on nude mice models of human gastric cancer. RESULTS: Both PDOX and DOX could significantly inhibit tumor growth compared with Control (P < 0.05) in both subcutaneous and orthotopic models. Animal survival was much better in PDOX group than DOX group. In peripheral blood test, PDOX group had significantly higher levels of platelets than the Control (P < 0.05), and lymphocyte lower than Control (P < 0.05). There were no significant differences on liver, kidney and cardiac function parameters among three groups (P > 0.05). Immunohistochemistry showed that treatment groups had much higher Tunel than Control (P < 0.05), and PDOX had significantly lower Ki-67 than doxorubicin and Control group (P < 0.01). Western blotting showed that PDOX caused much higher expressions of P53, P21, Aparf-1, pro- and cleaved-caspase 3, compared with DOX. CONCLUSION: Compared with DOX, PDOX has increased effects but much decreased toxicity in treating animal model of gastric cancer. MATERIALS AND METHODS: Animals in subcutaneous model were randomized into Control, doxorubicin, PDOX-L, PDOX-M, and PDOX-H groups. Animals in surgical orthotopic implantation model were randomized into Control, doxorubicin and, peptide-doxorubicin groups. The animals were treated, monitored and examined following a set protocol. |
format | Online Article Text |
id | pubmed-5788612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57886122018-02-07 Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer Zhang, Jue Yuan, Jing-Ping Wang, Qun Shao, Li-Hua Liu, Shao-Ping Firestone, Raymond A. Hong, Ya-Ping Li, Ji-Guo Xin, Yan-Chao Li, Yan Oncotarget Research Paper BACKGROUND: To compare the efficacy and toxicity of peptide-doxorubicin (PDOX) and doxorubicin (DOX) on nude mice models of human gastric cancer. RESULTS: Both PDOX and DOX could significantly inhibit tumor growth compared with Control (P < 0.05) in both subcutaneous and orthotopic models. Animal survival was much better in PDOX group than DOX group. In peripheral blood test, PDOX group had significantly higher levels of platelets than the Control (P < 0.05), and lymphocyte lower than Control (P < 0.05). There were no significant differences on liver, kidney and cardiac function parameters among three groups (P > 0.05). Immunohistochemistry showed that treatment groups had much higher Tunel than Control (P < 0.05), and PDOX had significantly lower Ki-67 than doxorubicin and Control group (P < 0.01). Western blotting showed that PDOX caused much higher expressions of P53, P21, Aparf-1, pro- and cleaved-caspase 3, compared with DOX. CONCLUSION: Compared with DOX, PDOX has increased effects but much decreased toxicity in treating animal model of gastric cancer. MATERIALS AND METHODS: Animals in subcutaneous model were randomized into Control, doxorubicin, PDOX-L, PDOX-M, and PDOX-H groups. Animals in surgical orthotopic implantation model were randomized into Control, doxorubicin and, peptide-doxorubicin groups. The animals were treated, monitored and examined following a set protocol. Impact Journals LLC 2017-12-14 /pmc/articles/PMC5788612/ /pubmed/29416744 http://dx.doi.org/10.18632/oncotarget.23319 Text en Copyright: © 2018 Zhang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Zhang, Jue Yuan, Jing-Ping Wang, Qun Shao, Li-Hua Liu, Shao-Ping Firestone, Raymond A. Hong, Ya-Ping Li, Ji-Guo Xin, Yan-Chao Li, Yan Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer |
title | Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer |
title_full | Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer |
title_fullStr | Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer |
title_full_unstemmed | Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer |
title_short | Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer |
title_sort | experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788612/ https://www.ncbi.nlm.nih.gov/pubmed/29416744 http://dx.doi.org/10.18632/oncotarget.23319 |
work_keys_str_mv | AT zhangjue experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer AT yuanjingping experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer AT wangqun experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer AT shaolihua experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer AT liushaoping experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer AT firestoneraymonda experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer AT hongyaping experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer AT lijiguo experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer AT xinyanchao experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer AT liyan experimentalevidenceofgoodefficacyandreducedtoxicitywithpeptidedoxorubicintotreatgastriccancer |